The present study aimed to compare the prevalence of oral problems between individuals with rare genetic diseases that affect skeletal development and individuals without rare diseases. A cross-sectional study was conducted with 210 individuals between two and fifty-four years of age: 105 with rare genetic diseases (27 with mucopolysaccharidosis [MPS] and 78 with osteogenesis imperfecta [OI]) and 105 without rare diseases. The rare genetic disease group was recruited from hospital units that provide care for patients with MPS and OI in five states of Brazil, and the other group was recruited from the same location. The participants were examined with regards to malocclusion, dental anomalies, dental caries, and gingivitis. A questionnaire was administered addressing individual, sociodemographic, and behavioral characteristics as well as dental history. A descriptive analysis was performed, followed by unadjusted and adjusted binary logistic regression analyses. The mean age was 14.1 ± 12.2 years. Individuals with a rare disease were 12.9-fold more likely to have some type of oral problem (95% CI: 3.7–44.7) compared to the group without rare diseases. The prevalence of oral problems was higher among Brazilians with MPS and OI compared to normotypical individuals.

Objective: To compare the prevalence of malocclusion and the facial profile of children/adolescents with rare genetic diseases—mucopolysaccharidosis (MPS) and osteogenesis imperfecta (OI) with normotypical children/adolescents. Design: Cross-sectional study. Setting: Hospital outpatient clinics in 5 Brazilian states (Ceará, Espírito Santo, Minas Gerais, Rio de Janeiro, and São Paulo). Participants:: A total of 152 children and adolescents aged between 2 and 19 years, 76 of whom had rare genetic diseases ([MPS (n = 19) / OI (n = 57)] and 76 with no rare genetic disease; and their parents/guardians. Interventions: None tested, observational study. Main Outcome Measure(s): Presence of malocclusion and subjective facial profile analysis. Parents/guardians answered a questionnaire on sociodemographic, behavioral issues, and their child's medical/dental history. Results: The average age of the children/adolescents was 8.9 years (±4.6). There were no confounding variables for the association between rare diseases and occlusal issues. The group with rare diseases showed a higher prevalence of occlusal alterations when compared to children/adolescents with no rare diseases. Children/adolescents with rare diseases showed a greater tendency to have a dolichofacial, convex facial profile, with increased lower anterior facial height and inadequate facial proportions when compared to individuals without a rare disease. Conclusions: Children/adolescents with MPS and OI had a higher prevalence of malocclusion and facial alterations when compared to children/adolescents without rare diseases.

The aim of this study is to compare the dental profiles of Brazilian patients with rare genetic skeletal disorders and normotypical patients. A cross-sectional study was carried out with 210 individuals aged between 2 and 54 years old [105 with rare diseases (Mucopolysaccharidosis/MPS n = 27 and Osteogenesis Imperfecta/OI n = 78) and 105 without rare diseases] and their parents/caregivers. The parents/caregivers answered a questionnaire about individual aspects of their child and the dental profile was identified from questions related to dental history and the presence/absence of dental problems. The patients’ oral cavity was also examined by three examiners for dental caries, malocclusion, gingivitis, and dental anomalies. The average age of individuals with a rare disease was 14.1 years (±12.2) and the median was 9.5 years. Participants who had already used the public health system (SUS) dental care services had a 2.24 times higher chance of belonging to the group with a rare disease (OR = 2.24; 95% CI: 1.07–4.89). Patients with rare diseases are 14.86 times more likely to have difficulty receiving dental treatment (OR = 14.86; 95% CI: 5.96–27.03) and 10.38 times more likely to have one or more dental problems (OR = 10.38; 95% CI: 1.95–35.17). Individuals with rare disorders have a greater history of difficulty in accessing dental treatment, using the SUS, and were diagnosed with more dental problems compared to normotypical individuals.

Background/Objectives: The use of nonsteroidal anti-inflammatory drugs (NSAIDs) is common in dentistry, mainly for pain and inflammation. However, their coadministration with warfarin may lead to serious potential drug-drug interactions (PDDIs), increasing the risk of bleeding. This study aimed to identify and describe the frequency of PDDIs between warfarin and NSAIDs prescribed by dentists and dispensed by the Unified Health System (SUS) in Minas Gerais, Brazil, from January 2011 to December 2021. Methods: A descriptive analysis was conducted using data from Integrated Pharmaceutical Services Management System (Sigaf), considering prescriptions of warfarin and NSAIDs issued during the same period. Results: The prescribed NSAIDs were diclofenac sodium 50 mg, diclofenac potassium 50 mg, ibuprofen 600 mg, nimesulide 100 mg, and nimesulide 50 mg/mL oral suspension. Warfarin sodium 5 mg is the prescribed oral anticoagulants. The results showed a marked increase in both warfarin (from 6017 to 59,945 prescriptions; +896%) and NSAID use (from 2644 to 84,408 prescriptions; +3093%), paralleling the rise in PDDIs, which grew from 2 in 2011 to 62 in 2021. Despite this 3000% relative increase, the absolute frequency of PDDIs remained low, corresponding to approximately 0.7 interactions per 1000 NSAID prescriptions in 2021. Conclusions: Although these PDDIs are low, they are clinically significant and may have important implications for patients and the healthcare system. In conclusion, PDDIs between NSAIDs and warfarin, though low in absolute numbers, have increased over the years, reinforcing the need for greater awareness among dental professionals and for the implementation of clinical decision support strategies to promote safe care.